News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
CANSINOBIO (06185.HK) Initiates Clinical Trial for PCV24, Completes First Patient Enrollment
CANSINOBIO (06185.HK) announced that its self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (PCV24) has recently officially initiated Ph...
Reset
Send
The window will close in 5 seconds
CANSINOBIO (06185.HK) Initiates Clinical Trial for PCV24, Completes First Patient Enrollment
Close
Recommend
5
Positive
3
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

CANSINOBIO (06185.HK)  -0.560 (-2.238%)    Short selling $2.67M; Ratio 11.068%   announced that its self-developed 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (PCV24) has recently officially initiated Phase I/II clinical trials and has completed enrollment of the first subject. (jl/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-03 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.